Biomea Fusion Inc (BMEA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Biomea Fusion Inc   (NASDAQ: BMEA)


Biomea Fusion Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Biomea Fusion Inc's ROI in the second quarter of 2026?
Biomea Fusion Inc recorded a cumulative net loss of $-33 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -86.18%.

Within the Healthcare sector Biomea Fusion Inc achieved the highest return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. .

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -34.89 % -37.28 % -54.88 % -63.3 % -63.77 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 26 37 48 40 56
Return On Investment (TTM) -86.18 % -99.76 % -138.57 % -202.86 % -193.31 %
BMEA's Overall Ranking # # # # #
Seq. Investment Change TTM -16.2 % 1.04 % -5.48 % -18.64 % -19.28 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -33 -45 -62 -96 -112

BMEA Company Profile >> Back to BMEA Roi Comparisons >> See Annual BMEA Return On Investment



Return On Investment BMEA's Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Investment Statistics
High Average Low
0 %
0 %
0 %
 



  News about Biomea Fusion Inc Return on Investment ROI

Breakthrough in Diabetes Management Presented at ATTD-ASIA 2024 as Biomea Fusion Inc Reports Financial Setbacks

November 18, 2024

Late-Breaker Oral Presentation Unveils New Insights from COVALENT-111 In a significant development for diabetes management, a late-breaker oral presentation showcased new analyses from the escalation portion of the COVALENT-111 trial at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024). Researchers highlighted that Icovamenib, a novel therapeutic agent, achieved a mean reduction in HbA1c levels greater than 1% at week 26, following just four weeks of administration in patients with Type 2 diabetes characterised by insulin deficiency.This promising data underscores Icovamenib s potential to offer improved glucose control for a patient population that has historically faced challenges in management. The implications of these findings may usher in a new era of therapeutic options for those struggling with this chronic condition, particularly in markets across Asia where the diabetic population continues to rise.

Biomea Fusions BMF-219 Clinical Trials Resume A Step Toward Innovation in Diabetes Treatment Amid Financial Challenges

September 26, 2024

In a noteworthy development for the biopharmaceutical landscape, Biomea Fusion, Inc. has announced the lifting of the FDA s clinical hold on its investigational covalent menin inhibitor, BMF-219. This decision paves the way for Biomea to resume its Phase I/II clinical trials focused on Type 2 and Type 1 diabetes referred to as COVALENT-111 and COVALENT-112, respectively. The FDA s endorsement marks a significant milestone for Biomea and offers hope for advancements in diabetes treatment options, as the company is dedicated to creating oral covalent small molecules aimed at improving the lives of patients grappling with metabolic diseases and genetically defined cancers.The reinstatement of these trials comes at a critical time, particularly given the financial challenges faced by Biomea Fusion. The company s cumulative net loss reached a staggering $108 million within just 12 months, ending in the third quarter of 2023, resulting in a concerning negative return on investment (ROI) of -66.55%. This situation highlights the competitive nature of the healthcare sector, where 679 other companies reported higher returns on investment during the same period.





Financial Statements
Biomea Fusion Inc's II. Quarter Investments $ 26 Millions BMEA's Balance sheet
Biomea Fusion Inc's II. Quarter Income $ -8 Millions Quarterly BMEA's Income Statement
BMEA's Income by Division See BMEA's Income by Division


BMEA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 30 58 177 110 181
Y / Y Investment Growth -49.28 % -67.09 % 60.67 % -39.14 % -
Net Income in Millions -62 -138 -117 -82 -42
Y / Y Net Income Growth - - - - -
Annual Return On Investment -209.11 % -237.58 % -66.22 % -74.25 % -22.96 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BMEA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BMEA's Competitors
Subscribers only: Roi for Biomea Fusion Inc's Suppliers
Subscribers only: Return On Investment for BMEA's Customers

Other Ratios
BMEA's Roa BMEA's Inventory Turnover Ratio BMEA's Growth Rates BMEA's Dividend Statistics
BMEA's Profitability Ratios BMEA's Asset Turnover Ratio BMEA's Dividend Growth
BMEA's Roe BMEA's Valuation Ratios BMEA's Financial Strength Ratios BMEA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-10T09:44:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.